Medication-Assisted Treatment: What MAT Is and Why It Works

She’d been to two inpatient programs. She’d done ninety meetings in ninety days. She’d tried everything that had ever been suggested to her, sincerely and with every intention of it working. She’d stay sober for a few weeks, sometimes a couple of months, and then the craving would return, overwhelming and relentless, and she’d use again. When her new doctor mentioned buprenorphine, she’d been skeptical. It sounded like trading one drug for another. That was eighteen months ago. She hasn’t used since.

Medication-assisted treatment, widely known as MAT, is the combination of FDA-approved medications with counseling and behavioral therapies to treat substance use disorders. It has one of the strongest evidence bases of any intervention in addiction medicine. It significantly reduces overdose deaths. It improves treatment retention. It reduces criminal involvement. And it remains widely misunderstood, underutilized, and stigmatized, particularly in communities where the ideology of abstinence-only recovery is strong.

Why Medication Matters

One of the persistent myths about addiction recovery is that using medication is not real recovery, that it simply substitutes one drug for another, or that a person who needs medication hasn’t truly committed to sobriety. This framing costs lives.

Opioid use disorder, in particular, involves deep neurobiological changes that go beyond behavioral patterns. The opioid receptors that have been flooded by drug use are now undersensitive. The brain’s natural endorphin system is suppressed. Withdrawal is physiologically severe. Craving can persist for months or years after the last use. Expecting a person to navigate all of this through willpower and counseling alone, without addressing the underlying neurobiology, is like treating hypertension with breathing exercises and refusing to discuss medication.

The research is unambiguous: for opioid use disorder, medications dramatically reduce mortality risk. Studies have found that buprenorphine reduces overdose mortality by approximately 50 percent. Methadone shows similarly robust findings. These are not marginal effects. They’re among the largest mortality reductions found in any area of addiction treatment research.

Medications for Opioid Use Disorder

Three medications are FDA-approved for opioid use disorder: buprenorphine, methadone, and naltrexone.

Buprenorphine is a partial opioid agonist, meaning it activates opioid receptors but with a ceiling effect. It reduces cravings and withdrawal symptoms without producing the euphoria of full agonists at therapeutic doses. It’s typically combined with naloxone (as Suboxone) to reduce misuse risk. Unlike methadone, as of 2023 any DEA-licensed prescriber with Schedule III authority — including primary care physicians, nurse practitioners, and physician assistants — can prescribe buprenorphine for opioid use disorder in an office-based setting, without any special certification. This change, enacted through the Mainstreaming Addiction Treatment Act (2023), significantly expanded access by eliminating the previous federal X-waiver requirement. People can pick up their prescription at a pharmacy and take it at home, which is a substantial quality-of-life advantage over daily methadone clinic attendance.

Methadone is a full opioid agonist with a long half-life. It reduces craving and withdrawal and, at an adequate dose, blocks the euphoric effects of other opioids. Because of its abuse potential and complex pharmacology, it’s dispensed daily in licensed methadone treatment programs, which requires patients to attend in person, often daily in early treatment. This requirement is a practical barrier for people with complicated lives, jobs, or transportation limitations. But for people who don’t respond to buprenorphine or who need the additional stability of a supervised setting, methadone can be life-saving.

Naltrexone (marketed as Vivitrol as a monthly injectable) is an opioid receptor antagonist. It blocks opioid receptors completely, so using opioids while on naltrexone produces no effect and no high. Because it doesn’t activate opioid receptors, it has no abuse potential and can be prescribed without special certification. The significant challenge is that the person must be fully through withdrawal before starting, which means several days of acute withdrawal discomfort. Adherence to oral naltrexone is poor; the monthly injectable form is much more effective. For people who are highly motivated and have completed detox, it’s a valuable option.

Medications for Alcohol Use Disorder

Alcohol use disorder has three FDA-approved medications: naltrexone, acamprosate, and disulfiram.

Naltrexone, the same medication used for opioid use disorder, also reduces alcohol craving and the rewarding effects of drinking. It works in the brain’s reward system to diminish the pleasure associated with alcohol use. Research supports both daily oral and monthly injectable formulations. It can be started while the person is still drinking, which removes the abstinence prerequisite that complicates other treatment initiation.

Acamprosate works differently, targeting the glutamate system that becomes dysregulated with heavy alcohol use and contributing to post-acute withdrawal discomfort. It’s most useful for people who have already completed detox and are trying to maintain abstinence. It doesn’t reduce craving in the same way naltrexone does but helps with the restlessness and dysphoria of early abstinence.

Disulfiram (Antabuse) works as a deterrent. It blocks the enzyme that metabolizes acetaldehyde, a byproduct of alcohol metabolism. When someone drinks on disulfiram, acetaldehyde accumulates rapidly, producing flushing, nausea, vomiting, and cardiovascular symptoms. The medication works only for people who choose to take it with full awareness of what it does. Supervised administration (a family member or pharmacist watching the person take it) substantially improves its effectiveness.

Despite existing for decades, these medications are prescribed for only a fraction of people with alcohol use disorder, with prescribing rates consistently estimated at under 10 percent of those who could benefit. Physician training, patient stigma, and systemic barriers all contribute to this treatment gap.

The Stigma Problem

“Trading one addiction for another” is probably the phrase that has done the most damage to medication-assisted treatment. People on buprenorphine or methadone hear it from family members, from peers in 12-step programs, sometimes from healthcare providers. Some treatment programs refuse to admit people who are on MAT or require them to taper off to participate.

This is not a stance supported by evidence. Buprenorphine at therapeutic doses doesn’t produce the impairment or euphoria associated with opioid addiction. The person is not high. They’re neurologically stabilized. The analogy to “substitution” misunderstands both how addiction works and how the medications work.

The practical consequences of the stigma are measurable: people who could benefit from MAT don’t seek it, delay seeking it, or discontinue it prematurely because of social pressure. In the context of a drug supply heavily contaminated with fentanyl, this delay or discontinuation is sometimes fatal.

MAT as Part of a Broader Approach

Medication-assisted treatment is not medication instead of treatment. The most effective approach combines medication with counseling, peer support, and the behavioral and psychosocial work of recovery. Medication stabilizes the neurobiology. Therapy and community support build the life that makes sustained recovery possible.

For someone newly stable on buprenorphine, having the mental and emotional bandwidth to engage meaningfully with therapy, to work on relationships, to start rebuilding, is often the difference that medication makes. The preoccupation with craving and withdrawal that consumed every available cognitive resource is now reduced enough for other work to happen.

If you or someone you love has struggled to maintain recovery without medication, it may be worth talking to a healthcare provider about MAT options. The goal is recovery that works, not recovery that fits a particular ideological template.

This article is for educational purposes only and is not a substitute for professional mental health treatment. If you are experiencing a mental health crisis, please reach out to a qualified mental health provider or call 988.